Laboratorio Clinico Y Bacteriologico Jaimar

Summary Statement of Deficiencies D0000 A Proficiency Test Desk Review off site survey was performed on October 5, 2026 to Laboratorio Clnico y Bacteriolgico Jaimar, the laboratory was found out of compliance with the following conditions: 42 CFR 493.803 Proficiency Testing, Successful Participation 42 CFR 493.1441 Laboratory Director, High Complexity D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- 2026), the laboratory failed to achieve satisfactory performance (80% or better) for two (2) out of two (2) consecutive testing events for the specialty of hematology in the analyte for Hematocrit (HCT) tests. Refer to D2130. D2130 HEMATOLOGY CFR(s): 493.851(f) (f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2026), the laboratory failed to achieve satisfactory performance (80% or better) for two (2) out of two (2) consecutive testing events for the specialty of hematology in the analyte for Hematocrit (HCT) tests. The findings include: 1. Review of the Casper Report 0155D and PRPTSP scores on September 27, 2026, confirmed that the laboratory had a PT (Proficiency Test) failure for the analyte Hematocrit (HCT) tests in the specialty of hematology. The laboratory obtained the following testing scores: Analyte: Hematocrit (HCT) a. First testing event year 2026 - 60% b. Second testing event year 2026 - 40% 2. A review of the PRPTSP records confirmed the above findings. D6076 LABORATORY DIRECTOR CFR(s): 493.1441 The laboratory must have a director who meets the qualification requirements of 493. 1443 of this subpart and provides overall management and direction in accordance with 493.1445 of this subpart. This CONDITION is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2026), the laboratory director failed to provide overall management and direction of the laboratory services. The laboratory director failed to ensure proficiency testing samples were tested as required. Refer to D6089. D6089 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under subpart H of this part; This STANDARD is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2026), the laboratory director failed to ensure successful participation in an HHS- approved proficiency testing program. Refer to D2130. -- 2 of 2 --

Summary Statement of Deficiencies D5413 TEST SYSTEMS, EQUIPMENT, INSTRUMENTS, REAGENT CFR(s): 493.1252(b) The laboratory must define criteria for those conditions that are essential for proper storage of reagents and specimens, accurate and reliable test system operation, and test result reporting. The criteria must be consistent with the manufacturer's instructions, if provided. These conditions must be monitored and documented and, if applicable, include the following: (1) Water quality. (2) Temperature. (3) Humidity. (4) Protection of equipment and instruments from fluctuations and interruptions in electrical current that adversely affect patient test results and test reports. This STANDARD is not met as evidenced by: Based on Immuno Card Mycoplasma manufacturer's instructions, general immunology quality control records review (years 2022-2023) and laboratory general supervisor interview on January 20, 2023 at 10:25 AM, it was determined that the laboratory failed to follow the manufacturer's instruction when patient's specimen were tested for Mycoplasma by Immuno Card Meridian method from January 3, 2022 to December 21, 2022. The findings include: 1. The laboratory use Immuno Card Mycoplasma (Meridian to perform Mycoplasma patient's sample test. 2. The manufacturer's instruction establishes that the Mycoplasma test must be at room temperature between 22 to 25 C reviewed at 10:25 AM. 2. On January 20, 2023 at 10: 30 AM, the Mycoplasma testing records showed that the laboratory did not follow the manufacturer's instructions when it processed the following patients specimens: Testing Temperature Date processed #samples 1/3/2022 20.9 C 1 1/7/2022 20.4 C 1 1 /8/2022 20.8 C 1 1/10/2022 20.8 C 3 1/11/2022 21.3 C 4 1/12/2022 20.5 C 3 3/2 /2022 20.8 C 2 3/25/2022 21.6 C 3 3/28/2022 20.8 C 8 3/30/2022 20.8 C 5 3/31 /2022 21.8 C 2 4/4/2022 21.8 C 6 4/5/2022 21.8 C 2 4/8/2022 21.8 C 2 4/9/2022 21.8 C 3 4/20/2022 21.0 C 8 4/21/2022 21.1 C 2 5/11/2022 25.5 C 11 5/16/2022 25.6 C 6 5/17/2022 25.6 C 7 5/18/2022 26.0 C 6 5/19/2022 25.9 C 2 5/25/2022 21.2 C 4 5/26/2022 21.1 C 6 5/27/2022 21.1 C 1 5/28/2022 21.2 C 4 6/4/2022 25.8 C 2 6 Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- /13/2022 25.3 C 5 6/16/2022 20.9 C 2 6/27/2022 21.8 C 2 8/6/2022 25.1 C 1 8/29 /2022 25.4 C 3 9/21/2022 26.0 C 2 9/30/2022 21.9 C 1 10/3/2022 25.9 C 4 10/8 /2022 21.3 C 1 10/22/2022 21.9 C 1 11/1/2022 25.2 C 6 11/2/2022 25.3 C 15 11/3 /2022 25.9 C 13 11/9/2022 25.0 C 14 11/25/2022 25.5 C 1 11/28/2022 25.1 C 9 12 /21/2022 21.3 C 7 3. The laboratory general supervisor confirmed on January 20, 2023 at 11:50 AM, that the laboratory did not follow the manufacturer's instructions for the temperature of processing. 4. The laboratory processed and reported patient's specimen for mycoplasma test 192 out of the manufacturer's temperature range from January 3, 2022 to December 21, 2022 reviewed at 11:50 AM. D5449 CONTROL PROCEDURES CFR(s): 493.1256(d)(3)(ii)(g) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- At least once a day patient specimens are assayed or examined perform the following for-- Each qualitative procedure, include a negative and positive control material; (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on General Immunology (Mycoplasma pneumoniae test) quality control records review (years 2022-2023) and laboratory general supervisor interview on January 20 2023 at 10:25 AM, it was determined that the laboratory failed to include an external positive and negative control material each day when performed Mycoplasma pneumoniae patient testing by Immuno Card Mycoplasma (Meridian). The findings include: 1. The laboratory performed Mycoplasma patient's tests by ImmunoCard Mycoplasma (Meridian). 2. The general immunology quality control records were reviewed from January 1, 2022 to January 19, 2023. Reviewed at 10:25 AM. 3. From January 1, 2022 to January 19, 2023, the records showed that the laboratory did not include a negative and positive control material each day of patient's testing since January 3, 2022. The laboratory include a negative and positive control only one time weekly. Reviewed at 11:30 AM. 4. The laboratory general supervisor confirmed on January 20, 2023 at 11:45 AM, that the laboratory failed to include a negative and positive control material each day of testing when performed Mycoplasma pneumonia test. 5. The laboratory did not include any control material, when 138 out 162 days patient's specimens were processed from January 3, 2022 to September 30, 2022. 6. The laboratory processed and reported four hundred sixty two (462) Mycoplasma patient's samples out of a total one thousand forty eight (1,148) patient's samples those days. D6072 TESTING PERSONNEL RESPONSIBILITIES CFR(s): 493.1425(b)(3) Each individual performing moderate complexity testing must adhere to the laboratory's quality control policies, document all quality control activities, instrument and procedural calibrations and maintenance performed. This STANDARD is not met as evidenced by: Based on Mycoplasma ImmunoCard (Meridian) manufacturer's instructions, general immunology quality control records review (years 2022-2023)and laboratory testing personnel interview on February 14, 2017 at 10:00 AM, it was determined that testing -- 2 of 3 -- personnel failed to follow quality control procedures. The findings include: 1. The laboratory failed to follow the manufacturer's instruction when patient's specimen were tested for Mycoplasma by Immuno Card Meridian method from January 3, 2022 to December 21, 2022. Refer D5413. 2. The laboratory failed to include an external positive and negative control material each day when performed Mycoplasma pneumoniae patient testing by Immuno Card Mycoplasma (Meridian). Refer D5449. D6093 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(5) The laboratory director must ensure that the quality control programs are established and maintained to assure the quality of laboratory services provided and to identify failures in quality as they occur. This STANDARD is not met as evidenced by: Based on Mycoplasma ImmunoCard (Meridian) manufacturer's instructions, general immunology quality control records review (years 2022-2023)and laboratorygenral supervisor interview at 10:50 AM on January 0, 2023, it was determined that laboratory director failed to ensure to follow the manufacturer's instruction when patient's specimen were tested for Mycoplasma by Immuno Card Meridian method from January 3, 2022 to December 21, 2022. The findings include: 1. The laboratory failed to follow the manufacturer's instruction when patient's specimen were tested for Mycoplasma by Immuno Card Meridian method from January 3, 2022 to December 21, 2022. Refer D5413. 2. The laboratory failed to include an external positive and negative control material each day when performed Mycoplasma pneumoniae patient testing by Immuno Card Mycoplasma (Meridian). Refer D5449. -- 3 of 3 --